Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Autologous Cell Therapies for Solid Tumors Create T Cells Resistant to T Cell Exhaustion with Dr. Tina Albertson Lyell TRANSCRIPT
Download PDFMar 20, 2023
Dr. Tina Albertson is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to find ways to counter the exhaustion that the T cells exhibit so that T cells can stay functional and kill the solid tumor cells.
Tina explains, "Our cell therapies are from the patient's own cells, so these are what we call autologous cell therapies. We take the cells from the patient and bring them, in our case to Seattle, to our manufacturing facility. We both genetically and epigenetically reprogram them during manufacturing so that the cells will be resistant to the suppressive microenvironment of the solid tumors."
" I think most people are familiar with the concept of stem cells, which can self-renew as well as make cells that are functional and can differentiate. So when we reprogram them, we make them more stem-like, and this allows us to infuse cells into the patient that should be more persistent and more functional."
"The second product we're also testing in trials is tumor infiltrating lymphocytes or TILs. This is a product where you need a piece of their cancer or their tumor and extract the T cells from the tumor itself. That requires surgery, then a piece of tissue is also sent to our manufacturing facility. Those T cells are extracted and expanded. That takes a little bit longer. But similarly, once those are expanded to the right cell number, we send them back to the site to be reinfused into the patient."
#Lyell #CellTherapy #SolidTumors #Oncology #Cancer #TCells #TCellExhaustion #AutologousCellTherapy
